Health care policy. Reforming off-label promotion to enhance orphan disease treatment

Science. 2010 Jan 15;327(5963):273-4. doi: 10.1126/science.1181567.

Authors

Bryan A Liang¹, Tim Mackey

Affiliation

¹ Institute of Health Law Studies, California Western School of Law, San Diego, CA 92101, USA. baliang@alum.mit.edu

PMID: 20075234
DOI: 10.1126/science.1181567

No abstract available

MeSH terms

Drug Approval
Health Policy*
Humans
Legislation, Drug
Off-Label Use* / legislation & jurisprudence
Orphan Drug Production / legislation & jurisprudence
Product Surveillance, Postmarketing
Rare Diseases / drug therapy*
United States
United States Food and Drug Administration